India Approves Roche's 7-Minute Subcutaneous Cancer Injection Tecentriq, Cutting Treatment Time by 85%
核心洞察
India's technical committee has cleared Roche to import and market Atezolizumab injection (Tecentriq) for subcutaneous administration, reducing cancer (搜索) treatment time from 30-60 minutes to just 7 minutes.
The approval comes with a condition requiring Roche to conduct a Phase IV clinical trial in India within three months of receiving marketing authorization.
The subcutaneous formulation can be administered outside hospital settings by healthcare professionals in community care facilities or patients' homes, potentially reducing treatment costs.
India's drug regulatory technical committee has granted clearance to Swiss pharmaceutical giant Roche to import and market its cancer (搜索) immunotherapy Atezolizumab injection (Tecentriq) through subcutaneous administration, marking a significant advancement in cancer treatment delivery for Indian patients.
Dramatic Reduction in Treatment Time
The approval represents a transformative shift in cancer (搜索) care administration, with the subcutaneous formulation reducing treatment time to approximately seven minutes compared to the 30-60 minutes typically required for standard intravenous infusion. This 85% reduction in administration time is expected to provide substantial relief to cancer patients across the country while improving treatment accessibility.
The technical committee, operating under the Director General of Health Services (DGHS (搜索)) and established in 2013 following Supreme Court directions, granted permission with the condition that Roche conduct a Phase IV clinical trial in India. The company must submit its Phase IV clinical trial protocol to the Central Drugs Standard Control Organisation (CDSCO (搜索)) within three months of receiving marketing authorization.
Enhanced Patient Convenience and Cost Reduction
According to government officials, the switch from intravenous to subcutaneous administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience. The subcutaneous formulation offers unprecedented flexibility in treatment settings, as Tecentriq may be administered by a healthcare professional outside of hospital environments, including community care settings or even at patients' homes.
"Switching from intravenous (IV) to subcutaneous (SC) administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience," a government official stated.
Clinical Applications and Regulatory Background
Atezolizumab is an immune checkpoint inhibitor (搜索) immunotherapy that works by blocking the immune system's natural brakes, enabling immune cells to better target and attack cancer (搜索) cells. The drug is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer (搜索) (NSCLC (搜索)) after prior chemotherapy, and serves as a monotherapy for first-line treatment of patients with metastatic NSCLC.
During the recent committee meeting, Roche presented its proposal for permission to import and market Atezolizumab injection (Tecentriq®) 1875 mg/15 mL vial for subcutaneous administration, requesting a local Phase III clinical trial waiver while committing to conduct Phase IV trials in India.
Global Regulatory Alignment
The committee evaluated pharmacokinetic-pharmacodynamic (PK/PD) results from both Asian and non-Asian populations from global clinical studies, noting no significant ethnic differences in PK parameters. This evaluation supported the regulatory decision, particularly given that Roche had already received USFDA (搜索) approval for the subcutaneous route on September 12, 2024.
The approval aligns India's regulatory framework with international standards while ensuring appropriate post-marketing surveillance through the mandated Phase IV trial requirement. This approach balances patient access to innovative cancer (搜索) treatments with robust safety monitoring in the Indian population.